How Much Do We Know About Clinical Response and Remission to Add-On Biologics in Severe Asthma in a Real-World Setting
- PMID: 38724156
- DOI: 10.1016/j.chest.2023.12.034
How Much Do We Know About Clinical Response and Remission to Add-On Biologics in Severe Asthma in a Real-World Setting
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: G. W. is supported by the National Natural Science Foundation of China (No. 81920108002). G. W. is on advisory boards for and has received speaker’s honoraria from AstraZeneca, GlaxoSmithKline, Chiesi, and Novartis, and has received research support from AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest. None declared (W. W. W.).
Comment on
-
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3. Chest. 2024. PMID: 37925144
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical